Stock Markets February 23, 2026

JPMorgan Cuts V.F. Corp Rating, Sees Longer Road to Margin Recovery at Vans

Analyst reduces price target and trims earnings and revenue forecasts as footwear brand faces extended declines

By Maya Rios VFC
JPMorgan Cuts V.F. Corp Rating, Sees Longer Road to Margin Recovery at Vans
VFC

JPMorgan downgraded V.F. Corporation to Underweight and lowered its price target to $18 from $19, citing slower-than-expected revenue growth and a protracted margin recovery for Vans. The bank revised down earnings estimates for fiscal 2027 and 2028, models lower revenue growth than consensus, and flagged regional softness and brand-specific headwinds that could delay margin expansion.

Key Points

  • JPMorgan downgraded V.F. Corporation to Underweight and cut the price target to $18 from $19.
  • The bank projects Vans revenue will fall 4.5% in fiscal 2027 and expects negative mid-single-digit declines to persist into the first half of fiscal 2027 before improving.
  • JPMorgan lowered fiscal 2027 EPS to $0.99 and fiscal 2028 EPS to $1.26, models average revenue growth of 2.5% over the next two fiscal years (below consensus 3.1%), and forecasts operating margin of 8.4% by fiscal 2028 versus management's 10% target.

JPMorgan moved V.F. Corporation to an Underweight rating and reduced its price target to $18 from $19, citing a weaker revenue trajectory and a longer timeline for margins to recover at key brands, most notably Vans.

The firm expects Vans revenue to decline 4.5% in fiscal 2027, a steeper drop than the Street's projection of only a slight decline. JPMorgan characterized the recovery at Vans as non-linear, expecting negative mid-single-digit declines to continue into the first half of fiscal 2027 before moderating later in the year.

JPMorgan noted that management has pointed to early signs of improved product traction and marketing progress under Brand President Sun Choe. However, the bank observed that much of the current footwear and apparel assortment was not developed fully under her oversight, given standard product lead times of roughly 18 months and her July 2024 start date.

On the profit front, the brokerage trimmed its fiscal 2027 earnings-per-share forecast to $0.99 from the Street's $1.03, and reduced its fiscal 2028 EPS estimate to $1.26 from $1.29. It now models average revenue growth of 2.5% over the next two fiscal years, below the consensus view of 3.1%.

JPMorgan also scaled back its operating margin outlook, projecting V.F.'s operating margin will reach 8.4% by fiscal 2028. That is short of the company's 10% operating margin target articulated at its October 2024 investor day.

The lowered price target was derived from a valuation of about 8 times JPMorgan's 2027 EBITDA forecast of roughly $1.1 billion. The bank noted this multiple sits below V.F.'s pre-pandemic three-year average multiple of 9 times, and that the company's forward growth and margin profile remains about 200 basis points below pre-pandemic levels.

Beyond Vans, JPMorgan highlighted moderating growth at Timberland and softer trends for The North Face in Europe and Asia-Pacific. The bank warned these pressures could further postpone margin expansion as V.F. reinvests in stores and marketing initiatives intended to restore traffic.


Sectors impacted: Apparel and footwear retail, consumer discretionary, and retail marketing and store operations.

Risks

  • Extended revenue weakness at Vans - continued declines could pressure overall company results and affect apparel and footwear retail performance.
  • Softer regional demand for The North Face in Europe and Asia-Pacific - weaker trends in these markets could delay margin expansion as the company reinvests in stores and marketing.
  • Moderating growth at Timberland - slower performance at this brand could further slow improvement in V.F.'s consolidated margins and cash flow recovery.

More from Stock Markets

Starfighters Space Share Price Drops After Founder Resigns From All Executive Roles Feb 23, 2026 FDA Issues Draft Framework to Expedite Approval Path for Individualized Genetic Therapies Feb 23, 2026 Markets Re-Route as Trump’s 15% Global Tariff Reintroduces Trade Uncertainty Feb 23, 2026 Raymond James Lowers Rating on Vertical Aerospace Amid Funding and Talent Concerns Feb 23, 2026 AbbVie to invest $380 million in two new API plants at North Chicago site Feb 23, 2026